Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Wilmington PharmaTech Plans New R&D-Manufacturing Complex in Newark, Delaware

02/26/2019
Wilmington PharmaTech, will invest $18 million on a new state-of-the-science research and manufacturing facility in Newark, Delaware. The company plans to hire up to 139 new associates.

A Contract Research/Manufacturing Organization, Wilmington PharmaTech provides integrated services to pharmaceutical companies and biotech firms to expedite new pharmaceutical product development. One of their main offerings is manufacturing of Active Pharmaceutical Ingredients and related materials under cGMP, which is an important aspect in the drug development process that is required to ensure product quality and provide consistency during formulation and manufacture.

PharmaTech currently employs 37 full-time staff in the United States in several Newark locations including a 16,000 square foot building at 229A Lake Drive, a 50,000 square foot facility on Sunset Lake Road (previously owned by DuPont) and a 40,000 square foot building at Pencader Drive.

"This marks the next wave of growth, positioning Wilmington PharmaTech as the leader in new drug manufacturing in the US," Said Hui-Yin Harry Li, Ph.D., President and CEO of Wilmington PharmaTech. "This expansion scales up operations and significantly enhances offerings to our clients in API manufacturing and related services. It also expands our portfolio of research, development, and potential commercial API services. PharmaTech's expansion plans fulfill the commitment to growth and its hallmark reputation for excellence for our employees, customers, partners and our community in the state of Delaware."

According to Delaware Prosperity Partnership, Wilmington PharmaTech requested a $300,400 performance-based grant to support adding new jobs and a grant of $360,000 for assistance with capital costs.

"Wilmington PharmaTech's expansion shows Delaware's distinctive strength in supporting biotechnology and pharmaceutical start-up companies and builds on a foundation that began more than 200 years ago with the DuPont Company," said Governor John Carney. "We remain committed to supporting job growth throughout Delaware."

Exclusive Research